Key result
HTLV-I/II and HIV antibody prevalence shows no difference between multiple sclerosis patients and healthy controls.
Why the study?
Human retroviruses may play a role in neurological disorders, prompting evaluation of the relationship between HTLV-I/II and HIV infections and multiple sclerosis.
Is there an association between the presence of HTLV-I/II or HIV antibodies and Multiple Sclerosis?
Case-Control (n=79)
No
Is there an association between the presence of HTLV-I/II or HIV antibodies and Multiple Sclerosis?
Answers are grounded in this paper and cite their sources.
This study found no evidence of an association between HTLV-I/II or HIV infections and Multiple Sclerosis in an Iranian cohort.
Background: Multiple Sclerosis (MS) is a multifactorial disease that causes neurological disability. Human retroviruses may have a role in the etiology of several acute and chronic neurological disorders. Objectives: We aimed to investigate the presence of HTLV-I/II and HIV antibodies in the sera of MS patients to assess the relationship between these infections and MS. Methods: This case-control study was conducted on serum samples of MS patients and individuals admitted to the same hospital with no symptoms of MS as the control group. Samples were examined for HIV and HTLV-I/II antibodies using ELISA kits. Results: A total of 79 people, including 38 MS patients and 41 healthy individuals, were evaluated. The frequency of HIV antibodies was 0.0% in both the case and control groups. The HTLV-I/II antibodies were detected in 1 patient in the control group and no patients in the MS group, with no statistically significant difference between the two groups (P: 0.999). Conclusions: This study could not establish a relationship between the presence of HTLV-I/II or HIV antibodies and MS.
No takes yet. Share an insight, caveat, or question.
Golmohammadi et al. (2023) conducted a case-control in Multiple Sclerosis (n=79). HTLV-I/II and HIV antibodies vs. Healthy controls was evaluated on Frequency of HTLV-I/II antibodies (p=0.999). The presence of HTLV-I/II and HIV antibodies was not significantly different between patients with multiple sclerosis and healthy controls, with 0% prevalence in the MS group (P=0.999).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: